The researchers have found that a drug commonly used to treat type 2 diabetes can potentially be used in the treatment of autoimmune disorders.
The researchers have found that the drug, canagliflozin (also known as Invokana), could be used to treat autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus as it targets T-cells, which form an essential component of the immune system. Canagliflozin is a drug that controls blood sugar levels in people with type 2 diabetes, however researchers have found an unexpected role for the drug involving the human immune system.
Existing research has reported that targeting T-cell metabolism in autoimmunity can lead to therapeutic benefits. T-cells are a type of white blood cell that help the body fight infections and diseases, but in autoimmune diseases they have been observed to attack healthy tissues.
The new study, funded published in the journal Cell Metabolism, found that canagliflozin dampens down T-cell activation, suggesting that the drug could be repurposed as a treatment for T-cell driven autoimmunity.
The senior author who led the study said: “Our findings are significant as they provide the foundation for the clinical development of canagliflozin for the treatment of certain autoimmune diseases. As the drug is already widely used and has a known safety profile in humans, it could potentially reach clinic quicker than any new drugs developed and bring valuable benefits more swiftly to patients with autoimmune disorders.”
The first author and postdoctoral researcher said: “Identifying new roles for drugs that are currently being used in other disease settings is an exciting area of research. Given that our research primarily targets the metabolism of immune cells, we hope that the potential therapeutic benefits of our findings are applicable to a wide range of conditions.”
The researchers are hopeful that canagliflozin will enter a clinical trial to treat certain autoimmune disorders in the future.
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00178-X
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fcanagliflozin-impairs-t&filter=22
Type 2 diabetes drug could treat autoimmune disorders
- 1,300 views
- Added
Latest News
A new brain circuit in mice…
By newseditor
Posted 08 May
Mechanism of choline entry…
By newseditor
Posted 07 May
Link between UTI and breast…
By newseditor
Posted 07 May
Sleep resets brain connections
By newseditor
Posted 07 May
Interplay of various enzyme…
By newseditor
Posted 07 May
Other Top Stories
How KRAS regulates sex differences in colon cancer
Read more
Mechanism of protection against breast and ovarian cancer
Read more
Loss of Y chromosome in men enables cancer to grow
Read more
Long noncoding RNA's role in cancer invasion
Read more
Tumor Metabolism Atlas!
Read more
Protocols
Single-cell adhesive profil…
By newseditor
Posted 07 May
Parasympathetic neurons der…
By newseditor
Posted 07 May
Non-invasive measurements o…
By newseditor
Posted 05 May
A validation strategy to as…
By newseditor
Posted 04 May
Generation of rat forebrain…
By newseditor
Posted 03 May
Publications
Astrocytic Slc4a4 regulates…
By newseditor
Posted 08 May
Diabetic retinopathy is a c…
By newseditor
Posted 08 May
A body-brain circuit that r…
By newseditor
Posted 07 May
Host response during unreso…
By newseditor
Posted 07 May
Sleep pressure modulates si…
By newseditor
Posted 07 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar